Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219

Showing 1-25 of 219 citing articles:

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 183
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 133
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Georgia Xourafa, Melis Korbmacher, Michael Roden
Nature Reviews Endocrinology (2023) Vol. 20, Iss. 1, pp. 27-49
Open Access | Times Cited: 92
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, et al.
American Heart Journal (2023) Vol. 267, pp. 1-11
Open Access | Times Cited: 87
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 80
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 59
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Matthias Blüher, Julio Rosenstock, Josef Hoefler, et al.
Diabetologia (2023) Vol. 67, Iss. 3, pp. 470-482
Open Access | Times Cited: 56
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Leili Gao, Byung‐Wan Lee, Manoj Chawla, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1500-1510
Open Access | Times Cited: 50
Sensory Nutrition and Bitterness and Astringency of Polyphenols
Naomi Osakabe, Takafumi Shimizu, Yasuyuki Fujii, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 234-234
Open Access | Times Cited: 20
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
David A. Milder, Tamara Y. Milder, S. Liang, et al.
Anaesthesia (2024) Vol. 79, Iss. 7, pp. 735-747
Open Access | Times Cited: 17
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Jeffrey I. Mechanick, W. Scott Butsch, Sandra M. Christensen, et al.
Obesity Reviews (2024)
Open Access | Times Cited: 16
Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control
Ryan J. Jalleh, Karen L. Jones, Christopher K. Rayner, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1981-1993
Open Access | Times Cited: 58
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
Lyudmila Viktorovna Nedosugova, Yuliya V. Markina, Л. А. Бочкарева, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1168-1168
Open Access | Times Cited: 49
Tirzepatide: A Systematic Update
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14631-14631
Open Access | Times Cited: 48
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Maurício Reis Pedrosa, Denise Reis Franco, Hannah Waisberg Gieremek, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 11, pp. 867-884
Closed Access | Times Cited: 47
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906
Arvid Jungnik, Jorge Arrubla, Leona Plum‐Mörschel, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 1011-1023
Open Access | Times Cited: 46
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 45
GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Amira Guirguis, et al.
Brain Sciences (2023) Vol. 13, Iss. 11, pp. 1503-1503
Open Access | Times Cited: 39
Beta-Glucans of Cereals: Functional and Technological Properties
Anna Lante, Elisa Canazza, Paolo Tessari
Nutrients (2023) Vol. 15, Iss. 9, pp. 2124-2124
Open Access | Times Cited: 37
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1832-1845
Open Access | Times Cited: 35
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions
Stefano Ciardullo, Emanuele Muraca, Michela Vergani, et al.
Gastroenterology report (2023) Vol. 12
Open Access | Times Cited: 31
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Sydney S. Wilbon, Mikhail G. Kolonin
Cells (2023) Vol. 13, Iss. 1, pp. 65-65
Open Access | Times Cited: 30
Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies
Nilanjan Ghosh, Leena Chacko, Hiranmoy Bhattacharya, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1126-1126
Open Access | Times Cited: 29
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102181-102181
Open Access | Times Cited: 25
Metabolically healthy obesity: Misleading phrase or healthy phenotype?
Cem Tanrıöver, Sidar Çöpür, Abduzhappar Gaipov, et al.
European Journal of Internal Medicine (2023) Vol. 111, pp. 5-20
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top